NASDAQ:AFMD
Affimed N.V. Stock News
$5.42
+0.120 (+2.26%)
At Close: May 03, 2024
Affimed: Remaining Bullish Despite Study Discontinuation
10:16pm, Thursday, 08'th Jul 2021
Affimed recently reported their Q1 earnings that revealed a solid beat on EPS and revenue. However, the company also announced that Genentech has stopped one of their partnered programs. Following the
Affimed: Current Fall And Future Prospects
11:01am, Wednesday, 07'th Jul 2021
Affimed did well in the last 12 months, but has been seeing a correction lately. Given a "data rich" 2021, the correction is not correct.
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2021 Results - Earnings Call Transcript
03:14pm, Thursday, 01'st Jul 2021
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2021 Results - Earnings Call Transcript
Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress
06:30am, Thursday, 01'st Jul 2021
HEIDELBERG, Germany, July 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, tod
Affimed Earnings Preview
11:59am, Wednesday, 30'th Jun 2021
Affimed (NASDAQ:AFMD) announces its next round of earnings this Thursday, July 01. Here is Benzinga's look at Affimed's Q1 earnings report.
Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021
06:30am, Tuesday, 22'nd Jun 2021
HEIDELBERG, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, tod
Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board
07:04am, Wednesday, 16'th Jun 2021
HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, tod
Affimed to Present at the Jefferies Virtual Healthcare Conference 2021
06:30am, Wednesday, 26'th May 2021
Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today tha
Affimed Announces Virtual Annual General Meeting of Shareholders
04:30pm, Thursday, 20'th May 2021
Heidelberg, Germany, May 20, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today tha
Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies
09:30am, Friday, 14'th May 2021
Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural kill
Could Affimed Be a Millionaire-Maker Stock?
06:26am, Friday, 14'th May 2021
This biotech stock has already produced some big returns this year.
Affimed (AFMD) Enters Overbought Territory
07:31am, Tuesday, 27'th Apr 2021
Affimed (AFMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Affimed: Wholly-Owned Pipeline Programs Support A Long-Term Investment
03:25pm, Sunday, 18'th Apr 2021
Affimed's wholly-owned pipeline programs continue to report impressive clinical data that supports a long-term investment. I believe is Affimed is trailblazing on a new approach in oncology. The compa
Why Affimed N.V. Stock Dropped Today
05:18pm, Thursday, 15'th Apr 2021
The company's latest quarterly update was less than impressive.
Affimed N.V. (AFMD) CEO Adi Hoess on Q4 2020 Results - Earnings Call Transcript
03:31pm, Thursday, 15'th Apr 2021
Affimed N.V. (AFMD) CEO Adi Hoess on Q4 2020 Results - Earnings Call Transcript
